Cardiogen vs Ipamorelin
Moderate Research vs Well Studied
synergistic Mechanism-based · 47% Cardiogen and Ipamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Cardiogen Ipamorelin
Weight 460 Da 711.85 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes ~2 hours
Chain 4 amino acids 5 amino acids
Type Tetrapeptide bioregulator Growth hormone secretagogue
Key Benefits
Cardiogen
01 Supports cardiac tissue repair and regeneration
02 Regulates cardiovascular gene expression
03 Improves myocardial function
04 May support post-cardiac event recovery
05 Epigenetic mechanism for targeted action
06 Works at DNA/nuclear level
07 Part of comprehensive anti-aging protocols
08 Well-researched Khavinson peptide
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Dosing Protocols
Cardiogen
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Side Effects
Cardiogen
Generally well-tolerated
Minimal side effects reported
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Contraindications
Active cardiac emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Research Evidence
Cardiogen Ipamorelin
Status Moderate Research Well Studied
References 3 studies 5 studies
Latest — October 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.